UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
April 28, 2011 (April 28, 2011)
Date of Report (date of earliest event reported)
NEUROGESX, INC.
(Exact name of Registrant as specified in its charter)
| Delaware | 001-33438 | 94-3307935 | ||
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) |
2215 Bridgepointe Parkway, Suite 200, San Mateo, California 94404
(Address of principal executive offices)
(650) 358-3300
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
On April 28, 2011, NeurogesX, Inc. issued a press release entitled “NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid.”
A copy of the press release, dated April 28, 2011, is filed as Exhibit 99.1, to this Current Report on Form 8-K and is incorporated by reference herein. The contents of the press release are deemed to be filed for purposes of the Securities Exchange Act of 1934, as amended.
Item 9.01. Financial Statements and Exhibits.
The following exhibits are filed as part of this Form 8-K.
Exhibit No. | Description | |
| 99.1 | Press Release entitled “NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid.” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NEUROGESX, INC. | ||||||
| Date: April 28, 2011 | By: | /s/ Stephen F. Ghiglieri | ||||
| Stephen F. Ghiglieri | ||||||
| Executive Vice President, Chief Operating Officer and Chief Financial Officer | ||||||
EXHIBIT LIST
Exhibit No. | Description | |
| 99.1 | Press Release entitled “NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid.” |